Aurora Cannabis (ACB) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Aurora Cannabis (ACB) over the past year, losing 4.5% versus a loss of 27.7%. Over five years, LFCR leads with a -34.4% price change compared with -93.7% for ACB. Aurora Cannabis is the larger company by market cap ($279.1 million vs $244.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | LFCR |
|---|---|---|
| Share price | $4.41 | $6.44 |
| Market cap | $279.15M | $244.11M |
| 1-day change | -1.14% | 0.00% |
| YTD return | +5.69% | -21.27% |
| 1-year return | -27.71% | -4.45% |
| 5-year return | -93.66% | -34.35% |
| EPS (TTM) | $-0.61 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.67 | $8.98 |
| 52-week low | $2.56 | $3.63 |
| Distance from 52-week high | -33.85% | -28.29% |
| Analyst consensus | buy | hold |
| Avg. price target upside | — | -2.48% |
| Average volume | 1.36M | 289.19K |
| Shares outstanding | 63.31M | 37.91M |
| Employees | 1,028 | 382 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed ACB by 23.3 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Health Care · Medicinal Chemicals and Botanical Products · 1,028 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ACB vs LFCR FAQ
Which is bigger, Aurora Cannabis or Lifecore Biomedical?
Aurora Cannabis (ACB) is larger, with a market capitalization of $279.15M compared with $244.11M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, ACB or LFCR?
LFCR returned -4.45% over the past 12 months, compared with -27.71% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Lifecore Biomedical in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Aurora Cannabis and Biotechnology: Pharmaceutical Preparations for Lifecore Biomedical.